Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Innovative Automated Insulin Delivery System for Type 2 Diabetes

NCT06853990 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.

Interventions

  • DEVICE twiist insulin delivery system

Study Locations (20)

California

  • Scripps Whittier Diabetes Institute — La Jolla
  • Hoag Memorial Hospital Presbyterian — Newport Beach
  • Sansum Diabetes Research Institute — Santa Barbara

Massachusetts

  • Massachusetts General Hospital — Boston
  • Boston Medical Center — Boston
  • Joslin Diabetes Center — Boston

Georgia

  • Emory University — Atlanta
  • Endocrine Research Solutions, Inc — Roswell

Michigan

  • University of Michigan — Ann Arbor
  • Henry Ford Health — Detroit

Minnesota

  • International Diabetes Center - Health Partners Institute — Minneapolis
  • Mayo Clinic — Rochester

Colorado

  • University of Colorado — Aurora

Florida

  • University of Miami — Miami

Idaho

  • Rocky Mountain Clinical Research, LLC — Idaho Falls

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-04-14
Est. Completion 2026-06
Phase NA

Sponsor

Deka Research and Development

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06853990

The ClinicalTrials.gov registry entry for NCT06853990 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deka Research and Development, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention — of which twiist insulin delivery system is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06853990 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Massachusetts, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06853990 about?

NCT06853990 is a clinical study titled "Innovative Automated Insulin Delivery System for Type 2 Diabetes". The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.

What is the current status of trial NCT06853990?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2025-04-14. Estimated completion is 2026-06.

What conditions does trial NCT06853990 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06853990?

The interventions under investigation include: twiist insulin delivery system (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06853990?

This trial is sponsored by Deka Research and Development, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06853990 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial